+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID05285358

Safety Study of Pressurized Aerosolized Nab-Paclitaxel Combined With Gemcitabine and Cisplatin for Adults With Biliary Tract Cancer Spread to the Peritoneum

Led by City of Hope Medical Center · Updated on 2026-08-03

12

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the side effects and safety of pressurized intraperitoneal aerosolized chemotherapy PIPAC using nab-paclitaxel along with standard chemotherapy drugs gemcitabine and cisplatin in adults with biliary tract cancer that has spread to the lining of the abdomen peritoneal metastases. This phase I trial aims to find out if delivering nab-paclitaxel as a fine mist directly into the abdomen can improve drug distribution and reduce side effects compared to traditional methods. Participants receive gemcitabine and cisplatin intravenously on days 1 and 8 of each 21-day cycle, and nab-paclitaxel is given via PIPAC on day 3 during the 1st, 3rd, and 5th cycles. Treatment may continue for up to 8 cycles if the disease does not progress and side effects remain manageable. The PIPAC procedure involves a laparoscopic surgery to deliver aerosolized chemotherapy directly inside the abdomen using a nebulizer and high-pressure injector. Throughout the study, participants will undergo imaging scans, surgical evaluations, blood tests, and quality of life assessments at several points before, during, and after treatment. Researchers will monitor adverse events, surgical complications, overall survival, progression-free survival, symptom changes, and physical activity levels using questionnaires and a wrist pedometer. Follow-up visits occur 4 weeks after treatment completion and then every 3 months for continued evaluation of treatment effects and safety.

CONDITIONS

Brief Title

Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here